Skip to main content
Back to Events

2021 ASCO Annual Meeting

Posters & Presentations

  • Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

    IDH1 and IDH2 Driven Intrahepatic Cholangiocarcinoma (IHCC): A Comprehensive Genomic and Immunoprofiling

    Authors

    Shalini Makawita, Mitesh J. Borad, Fernando Carapeto, Lawrence Kwong, Tanios S. Bekaii-Saab, Karthikeyan Murugesan, Jeffrey S. Ross, Natalie Danziger, Mason A. Israel, Kimberly McGregor, Filip Janku, Milind M. Javle

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Scottsdale, AZ

    Date | Time

    June 4 | 9:00 am EDT

    Abstract Number

    4009

    More Details
  • Track: Genitourinary Cancer—Prostate, Testicular, and Penile

    Ancestral characterization of the genomic landscape, comprehensive genomic profiling utilization, and treatment patterns may inform disparities in advanced prostate cancer: A large-scale analysis

    Authors

    Smruthy Sivakumar, Jessica Kim Lee, Jay A. Moore, Julia Hopkins, Justin Newberg, Alexa Betzig Schrock, Randy Vince, Idalid Ivy Franco, Crystal Selesteen Seldon, Jennifer Mills, Jeffrey Venstrom, Brandon Arvin Virgil Mahal

    Affiliations

    Foundation Medicine, Inc., Cambridge, MA; University of Michigan Cancer Center, Ann Arbor, MI; Dana Farber/Brigham and Women's Cancer Center, Boston, MA; University of Miami, Miami, FL; Harvard Radiation Oncology Program, Boston, MA

    Date | Time

    June 8 | 8:00 AM EDT

    Abstract Number

    5003

    More Details
  • Track: Prevention, Risk Reduction, and Hereditary Cancer

    Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (sBRCA) or other homologous recombination (HR)-pathway gene mutations (muts) treated with PARP inhibitors (PARPi)

    Authors

    Felipe Batalini, Russell Madison, Dean C. Pavlick, Ethan Sokol, Tamara Snow, Arjun Sondhi, Garrett M. Frampton, Colby Jenkins, Judy Ellen Garber, Gerburg M. Wulf, Jeffrey Michael Venstrom, Nadine M. Tung, Emily Castellanos, Alexa Betzig Schrock, Kimberly McGregor

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Flatiron Health, New York, NY; Dana Farber Cancer Institute, Boston, MA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    10512

    More Details
  • Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

    Prevalence of inferred clonal hematopoiesis (CH) detected on comprehensive genomic profiling (CGP) of solid tumor tissue or circulating tumor DNA (ctDNA)

    Authors

    Emmanuel S. Antonarakis, Zheng Kuang, Hanna Tukachinsky, Christine Parachoniak, Andrew David Kelly, Ole Gjoerup, Aparna Aiyer, Eric Allan Severson, Dean C. Pavlick, Garrett M. Frampton, Jeffrey Michael Venstrom, Geoffrey R. Oxnard

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    3009

    More Details
  • Track: Breast Cancer

    Comprehensive genomic profiling (CGP) of 275 male breast cancer (BC) tissue (TBx) and liquid (LBx) biopsies: Comparative analysis to a female cohort (FBC) and therapeutic considerations

    Authors

    Arun Kadamkulam Syriac, Allison Clark, Mehrad Tavallai, Dexter X. Jin, Ethan Sokol, Kimberly McGregor, Jeffrey S. Ross, Natalie Danziger, Jose Pablo Leone

    Affiliations

    Foundation Medicine, Cambridge, MA; Dana Farber Cancer Institute/St. Elizabeth Hospital, Boston, MA; Natera, San Carlos, CA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    539

    More Details
  • Track: Breast Cancer

    Concordance of HER2+ status by IHC/ISH and ERBB2 status by NGS in a real-world clinicogenomic database and analysis of outcomes in patients (pts) with metastatic breast cancer (mBC)

    Authors

    Cheryl D. Cho-Phan, Jeremy Snider, Liangliang Zhang, Kimberly McGregor, Alexa Betzig Schrock, Emily Castellanos

    Affiliations

    Foundation Medicine, Cambridge, MA; Flatiron Health, San Francisco, CA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    1036

    More Details
  • Track: Breast Cancer

    Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm)

    Authors

    Hope S. Rugo, Kira Raskina, Alexa Betzig Schrock, Mason A. Israel, Ethan Sokol, Smruthy Sivakumar, Ashley Ward, James Creeden, Geoffrey R. Oxnard, Kimberly McGregor, Jeffrey Michael Venstrom, Hanna Tukachinsky

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; University of California, San Francisco, CA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    1068

    More Details
  • Track: Breast Cancer—Local/Regional/Adjuvant

    Predominance of RAD21 and ERBB2 Amplification and Progesterone Receptor Positivity in Tumors of the Right Breast Support Breast Cancer Lateralization

    Authors

    Zachary Spigelman, Jo-Ellen Murphy

    Affiliations

    Foundation Medicine, Cambridge, MA; Lahey Hospital and Medical Center, Burlington, MA

    Abstract Publication Only

    Abstract Number

    e12557

    More Details
  • Track: Developmental Therapeutics—Immunotherapy

    Genomic immunotherapy (IO) biomarkers detected on comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA)

    Authors

    Takayuki Yoshino, Hanna Tukachinsky, Jessica Kim Lee, Ethan Sokol, Dean C. Pavlick, Aparna Aiyer, David Fabrizio, Jeffrey Michael Venstrom, Saori Mishima, Yoshiaki Nakamura, Geoffrey R. Oxnard

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; National Cancer Center Hospital East, Kashiwa, Japan; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    2541

    More Details
  • Track: Developmental Therapeutics—Immunotherapy

    Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB)

    Authors

    Vaia Florou, Charalampos S. Floudas, Asaf Maoz, Abdul Rafeh Naqash, Gregory Hildebrand, Ethan Sokol, Garrett M. Frampton, Sonam Puri, Umang Swami, Breelyn A. Wilky, Peter Joel Hosein, Jonathan C. Trent, Gilberto Lopes, Wungki Park, Ignacio Garrido-Laguna

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; Huntsman Cancer Institute University of Utah, Salt Lake City, UT; Genitourinary Malignancies Branch, NCI, NIH, Bethesda, MD; Dana Farber Cancer Institute, Boston, MA; National Cancer Institute, Bethesda, MD; University of Kansas Medical Center, Kansas City, KS; University of Colorado, Aurora, CO; University of Miami, Miami, FL; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    2599

    More Details
  • Track: Developmental Therapeutics—Immunotherapy

    Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression

    Authors

    Richard S.P. Huang, Brennan Decker, Karthikeyan Murugesan, Matthew Hiemenz, Douglas A. Mata, Gerald Li, James Creeden, Shakti H. Ramkissoon, Jeffrey S. Ross

    Affiliation

    Foundation Medicine, Inc, Cambridge, MA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    2605

    More Details
  • Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

    Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting

    Authors

    Razelle Kurzrock, Amy R. MacKenzie, Adham Adel Jurdi, Basem Goueli, Walter Bordogna, Magalie Hilton, Erika Ferreira, Venice Rosalie Archer, Bettyna Brivet-Jones, Johannes Noe, Abba Elizabeth Theogaraj, Lincoln Pasquina, Christine M. Lovly

    Affiliations

    University of California San Diego, Moores Cancer Center, La Jolla, CA; Thomas Jefferson University, Philadelphia, PA; Austin Cancer Center, Austin, TX; Great Lakes Cancer Center and University of Buffalo, Buffalo, NY; F. Hoffmann-La Roche Ltd., Basel, Switzerland; Roche Products Ltd., Welwyn Garden City, United Kingdom; Foundation Medicine Inc., Boston, MA; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    TPS3155

    More Details
  • Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

    Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study

    Authors

    Philippe E. Spiess, Petros Grivas, Douglas A. Mata, Gennady Bratslavsky, Joseph M Jacob, Andrea Necchi, Natalie Danziger, Douglas I. Lin, Brennan Decker, Ethan Sokol, Richard S.P. Huang, Jeffrey S. Ross

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; Moffitt Cancer Center, Tampa, FL; University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA; Upstate Medical University, Syracuse, NY; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    3130

    More Details
  • Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

    Frequency of longitudinal changes in TP53 mutation status from gene sequencing of serial tumor biopsies from a large cohort of cancer patients

    Authors

    D. Allen Allen Annis, Dean C. Pavlick, Garrett M. Frampton, Lee A. Albacker, Vojislav M. Vukovic, Manuel Aivado

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; Aileron Therapeutics, Inc., Cambridge, MA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    3124

    More Details
  • Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

    TCF-001 TRACK (Target Rare Cancer Knowledge): A national patient-centric precision oncology trial for rare cancers

    Authors

    Vivek Subbiah, Roman Groisberg, Catherine Skefos, James M. Cleary, Ishwaria Mohan Subbiah, Jim Palma, Mary Oster, Steven W. Young, Julia Andrea Elvin, Jason K. Sicklick, Sarah Gaffey, Ashley Ward, Brian Michael Alexander, J. Jack Lee, Pradip De, Shumei Kato, Razelle Kurzrock

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; The University of Texas MD Anderson Cancer Center, Houston, TX; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Dana-Farber Cancer Institute, Boston, MA; TargetCancer Foundation, Cambridge, MA; University of California, San Diego, CA; Avera Cancer Institute, Sioux Falls, SD; University of California San Diego, Moores Cancer Center, La Jolla, CA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    TPS3143

    More Details
  • Track: Gastrointestinal Cancer—Colorectal and Anal

    Concurrent BRAFV600E and BRCA mutations in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Prevalence and case series of mCRC (pts) with prolonged overall survival (OS)

    Authors

    Timothy Lewis Cannon, Jamie Randall, Ethan Sokol, Sonja Alexander, Raymond Couric Wadlow, Daniel Barnett, Danny Rayes, John F. Deeken, Halla Nimeiri, Kimberly McGregor

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; Inova Schar Cancer Institute, Fairfax, VA; Virginia Commonwealth Universiry, Richmond, VA; University of Virginia Medical School, Charlottesville, VA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    3561

    More Details
  • Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

    ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA)

    Authors

    Samuel J Klempner, Liangliang Zhang, Ryon Graf, Russell Madison, Jeremy Snider, Cheryl D. Cho-Phan, Emily Castellanos, Gerald Li, Halla Nimeiri, Garrett M. Frampton, Geoffrey R. Oxnard, Jeffrey Michael Venstrom, Kimberly McGregor, Alexa Betzig Schrock

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; Massachusetts General Hospital, Boston, MA; Flatiron Health, San Francisco, CA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    4045

    More Details
  • Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

    Genomic alterations for novel targeted therapies in pancreatobiliary cancers from real-world data

    Authors

    Kumiko Umemoto, Hiroyuki Yamamoto, Ritsuko Oikawa, Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Takashi Ogura, Takuro Mizukami, Naoki Izawa, Jay A. Moore, Ethan Sokol, Yu Sunakawa

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; St. Marianna University School of Medicine, Kawasaki, Japan

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    4124

    More Details
  • Track: Genitourinary Cancer—Prostate, Testicular, and Penile

    Concordance of DNA Damage Repair (DDR) Gene Mutations in Paired Primary and Metastatic Prostate Cancer (PC) Samples

    Authors

    Michael Thomas Schweizer, Smruthy Sivakumar, Hanna Tukachinsky, Ilsa Coleman, Navonil De Sarkar, Evan Y. Yu, Eric Quentin Konnick, Peter Nelson, Colin C. Pritchard, Robert B. Montgomery

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    5020

    More Details
  • Track: Genitourinary Cancer—Prostate, Testicular, and Penile

    Genomic Landscape of MSH6-mutated clinically advanced castrate resistant prostate cancer (mCRPC)

    Authors

    Gennady Bratslavsky, Brennan Decker, Joseph M Jacob, Andrea Necchi, Philippe E. Spiess, Petros Grivas, Douglas I. Lin, Shakti H. Ramkissoon, Eric Allan Severson, Richard S.P. Huang, Douglas A. Mata, Russell Madison, Meagan Montesion, Ole Gjoerup, Ethan Sokol, Dean C. Pavlick, Natalie Danziger, Jeffrey S. Ross

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; SUNY Upstate University Hospital, Bethesda, MD; Upstate Medical University, Syracuse, NY; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Moffitt Cancer Center, Tampa, FL; University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    5062

    More Details
  • Track: Genitourinary Cancer—Prostate, Testicular, and Penile

    Molecular, immunologic, and clinicodemographic landscape of MYC-amplified (MYCamp) advanced prostate cancer (PCa)

    Authors

    Brandon Arvin Virgil Mahal, Liangliang Zhang, Mohamed Alshalalfa, Ryon Graf, Hanna Tukachinsky, Richard S.P. Huang, Kimberly McGregor, Alexa Betzig Schrock, Jeffrey Michael Venstrom

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; University of Miami, Miami, FL

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    5041

    More Details
  • Track: Genitourinary Cancer—Prostate, Testicular, and Penile

    Using real-world outcomes to evaluate the predictive power of tissue-assessed genomic biomarkers for taxane versus novel hormonal therapy (NHT) outcomes in metastatic castration-resistant prostate cancer (mCRPC)

    Authors

    Ryon Graf, Virginia Fisher, Ole Gjoerup, Alexa Betzig Schrock, Russell Madison, Samantha Morley, Lei Zhong, Geoffrey R. Oxnard, Jeffrey Michael Venstrom, Amado J. Zurita

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; Dana-Farber Cancer Institute, Boston, MA; The University of Texas MD Anderson Cancer Center, Houston, TX

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    5054

    More Details
  • Track: Gynecologic Cancer

    Assessment of predictive biomarker prevalence in molecularly defined adult-type ovarian granulosa cell tumors

    Authors

    Robert Tyler Hillman, Douglas I. Lin, David Marc Gershenson

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; MD Anderson Cancer Center, Houston, TX

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    5567

    More Details
  • Track: Health Services Research and Quality Improvement

    Association of electronic-health record (EHR)-derived race with BRCA testing in patients (pts) with breast cancer (BC) with similar genetic ancestry (GA) in a clinicogenomic database (CGDB)

    Authors

    Yanling Jin, Charlotta Fruchtenicht, Sylvia Hu, Janis Allen, Anne-Marie Meyer, Altovise Ewing, Melanie Huntley

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; F. Hoffmann-La Roche Ltd., Basel, Switzerland; Genentech, Inc., South San Francisco, CA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    6524

    More Details
  • Track: Lung Cancer

    Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype

    Authors

    Ibiayi Dagogo-Jack, Russell Madison, Douglas A. Mata, Alexa Betzig Schrock, Tyler Janovitz, Brennan Decker, Richard S.P. Huang, Douglas I. Lin, Jonathan Keith Killian, Shakti H. Ramkissoon, Ole Gjoerup, Natalie Danziger, Jeffrey Michael Venstrom, Brian M. Alexander, Jeffrey S. Ross

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; Massachusetts General Hospital, Boston, MA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    8555

    More Details
  • Track: Lung Cancer

    Genomic landscape of non-small cell lung cancer (NSCLC) with methylthioadenosine phosphorylase (MTAP) deletion

    Authors

    Stephen L. Graziano, Dean C. Pavlick, Ethan Sokol, Shakti H. Ramkissoon, Eric Allan Severson, Richard S.P. Huang, Douglas A. Mata, Brennan Decker, Kimberly McGregor, Natalie Danziger, Jeffrey S. Ross

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; Regional Oncology Center, Syracuse, NY

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    9116

    More Details
  • Track: Lung Cancer

    Incidence and heterogeneity of C797S and other EGFR resistance mutations on routine comprehensive genomic profiling (CGP)

    Authors

    Pasi A. Janne, Jessica Kim Lee, Russell Madison, Jeffrey Michael Venstrom, Alexa Betzig Schrock, Geoffrey R. Oxnard

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; Dana-Farber Cancer Institute, Boston, MA

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    9101

    More Details
  • Track: Prevention, Risk Reduction, and Hereditary Cancer

    Identification of potential germline (GL) variants by routine clinical comprehensive genomic profiling (CGP) and confirmatory GL testing in 24 tumor types

    Authors

    Kristen Hanson, Michael Mullane, Erica Schnettler, Dean C. Pavlick, Garrett M. Frampton, Maureen Cooper, Deborah Wham, Michael A. Thompson, Jennifer Godden, Mary Walters, Jeffrey Michael Venstrom, Kimberly McGregor

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; Advocate Aurora Health, Milwaukee, WI

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    10596

    More Details
  • Track: Prevention, Risk Reduction, and Hereditary Cancer

    Rare BAP1 variant of unknown significance (VUS) and analysis of BAP1 codon 146 genomics: Potential germline and therapeutic implications

    Authors

    Jo-Ellen Murphy, Sara Sadan, Jessica Kim Lee, Jana Pruski-Clark, Rebecca Sutphen, Kimberly McGregor

    Affiliations

    Foundation Medicine, Inc, Cambridge, MA; Oncology and Hematology of White Plains PLLC, White Plains, NY; InformedDNA, St. Petersburg, FL

    Date | Time

    June 4 | 9:00 AM EDT

    Abstract Number

    10533

    More Details